“The algorithm-based approaches that people are taking are suboptimal,” says Drew Hannaman, head of R&D at Ichor Medical Systems, which obtained an empirical neoantigen selection platform after Genocea’s bankruptcy last year. “[Algorithm-based approaches] are pretty good at identifying a property that is necessary to generate immune response. But they are not comprehensive enough to identify the properties that are necessary and sufficient.” The result, Hannaman says, is “a lot of false positives”.
@cyrilpedia Is there a non-paywalled version of this article?
@cyrilpedia Weird, it's asking me for 8$ to buy the PDF xD